investors

Investor Overview

We are currently in a closed period. Normal Investor Relations meetings and activities will resume from 17 September 2018 following the release of our FY2018 Annual Results.

We are well positioned in both developing and developed markets. As the largest pharmaceutical company in Africa, we have an expanding presence in Latin America, Asia, Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics (“CIS”). We are also one of the leading pharmaceutical companies in Australia and are establishing a presence in other developed markets such as the United States of America (“USA”) and Canada.

With an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life, we continue to increase the number of lives benefiting from our products, reaching more than 150 countries across the world.

Our year end results for the period ended 30 June 2018 will be announced at a presentation and webcast on Thursday, 13 September 2018.

The presentation will be available for download here and on the home page of this website from 13 September 2018.

INVESTMENT PROPOSITION

Strong market position


Diversified geographies and product offering


Proven track record


Leverages on local knowledge and expertise

Centralised Group activities facilitate synergies and mitigate pricing pressures


Positive growth drivers


Responsible corporate citizen


Other considerations

INVESTOR CALENDAR

8 March 2018

Interim results announcement

9 March 2018

Interim results presentation in Cape Town

30 June 2018

Financial year end

13 September 2018

Year end results announcement, presentation and webcast at the JSE, Johannesburg. The webcast will be available from 08:30 until 31 October 2018.

November 2018

Publishing of the Integrated Report

6 December 2018

Annual General Meeting

SENS ANNOUNCEMENTS

SHARE PRICE CENTRE

View share price information for Aspen Holdings.

SHARE CODE

APN ISIN: ZAE 000066692

JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.

PRESENTATIONS

PDF 3MB

CAPITAL DISTRIBUTIONS

Delivering double-digit earnings growth to our shareholders for 17 consecutive years

SHAREHOLDER STATISTICS

Analysis of shareholders at 30 June 2016

CORPORATE INFORMATION

All corporate information and contact details

CONTACT DETAILS

Zihle Mgcokoca
+27 31 580 8600
ZMgcokoca@aspenpharma.com